Mendlewicz J
Department of Psychiatry, Erasme Hospital, Brussels, Belgium.
Int Clin Psychopharmacol. 1995 Mar;10 Suppl 2:5-13. doi: 10.1097/00004850-199503002-00003.
Venlafaxine is a structurally novel phenylethylamine agent with antidepressant properties. The preclinical profile suggests that it will be as effective as the tricyclic antidepressants (TCAs) with few significant effects on the neuroreceptors that mediate many of the side effects common with the TCAs. Venlafaxine has been studied in more than 2500 patients in clinical trials; its efficacy has been evaluated in more than 700 venlafaxine-treated patients in six placebo-controlled trials (five in out-patients and one in in-patients). These studies used a wide range of doses (25-375 mg/day) and different dose regimens (t.i.d. and b.i.d). The results of these studies clearly establish that venlafaxine is significantly more effective than placebo. In the two studies that used doses of 375 mg/day, a significant difference from placebo was observed on the Montgomery- Asberg Depression Rating Scale (MADRS) at the earliest time points assessed, after 4 days of treatment in the in-patient study and after 1 week of treatment in the out-patient study. Venlafaxine also appears to be as effective as some reference antidepressants. A positive dose-response effect has been demonstrated with doses of up to 375 mg/day, with a minimum effective dose of 75 mg/day.
文拉法辛是一种具有抗抑郁特性的结构新颖的苯乙胺类药物。临床前资料表明，它的疗效与三环类抗抑郁药（TCAs）相当，而对介导TCAs许多常见副作用的神经受体几乎没有显著影响。文拉法辛已在超过2500名患者中进行了临床试验研究；在六项安慰剂对照试验（五项门诊试验和一项住院试验）中，对700多名接受文拉法辛治疗的患者评估了其疗效。这些研究使用了广泛的剂量（25 - 375毫克/天）和不同的给药方案（每日三次和每日两次）。这些研究结果清楚地表明，文拉法辛比安慰剂显著更有效。在两项使用375毫克/天剂量的研究中，在评估的最早时间点，住院研究治疗4天后和门诊研究治疗1周后，蒙哥马利 - 阿斯伯格抑郁评定量表（MADRS）上观察到与安慰剂有显著差异。文拉法辛似乎也与一些对照抗抑郁药疗效相当。已证明剂量高达375毫克/天时有正性剂量反应效应，最小有效剂量为75毫克/天。
